Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization. The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalizations at Month 30. Attruby demonstrated rapid benefits within 3 months and achieved a 50% reduction in cardiovascular-related hospitalization events. As the first approved product with near-complete TTR stabilization (≥90%), Attruby preserves native TTR function. BridgeBio will receive a $500 million payment under their royalty funding agreement and has submitted for European approval, expected in 2025.
BridgeBio Pharma (BBIO) presented positive initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM. Key results show that acoramidis achieved a 36% reduction in All-Cause Mortality at Month 36 and demonstrated the earliest known time to separation in cardiovascular outcomes (3 months). The study showed a 46% reduction in the composite endpoint of mortality and cardiovascular-related hospitalizations at Month 36, increasing to 48% at Month 42. The drug continues to be well-tolerated with no new safety concerns. A New Drug Application is under FDA review with a PDUFA date of November 29, 2024.
BridgeBio Pharma (BBIO) has published positive 18-month results from its Phase 2 PROPEL 2 trial of infigratinib for children with achondroplasia in the New England Journal of Medicine. The study showed statistically significant results with a +2.50cm/year increase in annualized height velocity at Month 18 using a 0.25mg/kg daily oral dose. The treatment demonstrated improved body proportionality and was well-tolerated with no serious adverse events. The drug has received multiple FDA designations, including Breakthrough Therapy Designation. The company's Phase 3 PROPEL 3 study continues enrollment, expected to complete by end of 2024.
BridgeBio Pharma (BBIO) reported Q3 2024 financial results with revenue of $2.7M and a net loss of $162.0M. Cash position ended at $405.7M. The company's lead drug acoramidis showed positive Phase 3 results in ATTR-CM with FDA PDUFA date set for November 29, 2024. Upon approval, BBIO anticipates receiving a $500M milestone payment and $105M in additional regulatory milestones for European and Japanese territories.
Three Phase 3 readouts are expected in 2025. Notable pipeline progress includes completed screening for CALIBRATE Phase 3 trial of encaleret, completed enrollment for FORTIFY Phase 3 trial, and Breakthrough Therapy Designation for infigratinib in achondroplasia.
BridgeBio Pharma (BBIO) announced the publication of a case study in The Journal of Portfolio Management, exploring how portfolio theory impacts biomedical innovation. The study, co-authored by BridgeBio's senior management and MIT professor Andrew Lo, examines the company's unique business model that applies portfolio theory to drug development. Founded in 2015, BridgeBio's approach involves diversifying risk by investing in multiple uncorrelated drug development programs, rather than focusing on a single lead candidate. This strategy aims to increase success probability, create stable returns, and attract broader investment, particularly for early-stage genetic disease research.
BridgeBio Pharma presented positive preliminary data from eleven participants in the CANaspire Phase 1/2 clinical trial of BBP-812, an investigational gene therapy for Canavan disease. The study showed significant motor function improvements and milestone achievements at 12-months post-treatment, contrasting with the natural disease progression observed in their CANinform study.
Key findings include sustained reductions in N-acetylaspartate levels across urine, cerebrospinal fluid, and brain, with urine NAA reduced by 64% in low dose and 73% in high dose cohorts. The therapy demonstrated improved myelination and continued motor function progress, with some children achieving independent sitting and walking. BBP-812 was generally well-tolerated and has received multiple FDA designations including RMAT, Orphan Drug, and Fast Track.
BridgeBio Pharma (Nasdaq: BBIO) announced that outcomes data through 42 months from the open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the 2024 AHA Scientific Sessions. The featured science oral presentation, titled 'Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study', will be delivered by Dr. Daniel Judge on November 18.
Additionally, BridgeBio will present three moderated digital posters on ATTR-CM, covering topics such as healthcare costs, baseline risk evolution, and acoramidis' impact on survival. These presentations will take place on November 17. The presentation and posters will be available on BridgeBio's website after the sessions.
BridgeBio Pharma announced the completion of enrollment for its Phase 3 FORTIFY study evaluating BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). The study exceeded its target enrollment, with topline data expected in 2025. BBP-418 could potentially receive Accelerated Approval in the U.S. based on the biomarker glycosylated alpha-dystroglycan (αDG). If successful, BBP-418 would be the first approved therapy for LGMD2I/R9 in the U.S. The study's primary endpoint is the North Star Assessment for limb-girdle type muscular dystrophies, evaluated at 36 months. BBP-418 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the EMA. The completion announcement coincided with the 10th annual LGMD Awareness Day on September 30, 2024.
BridgeBio Pharma (Nasdaq: BBIO) has announced that the FDA granted Breakthrough Therapy Designation to oral infigratinib for children with achondroplasia. This designation, based on preliminary clinical evidence from the PROPEL 2 trial, is designed to expedite development and regulatory review. In Cohort 5 of PROPEL 2, infigratinib showed a statistically significant increase in annualized height velocity (AHV) and improved body proportionality. The global Phase 3 study, PROPEL 3, is enrolling on schedule. If approved, infigratinib could become the first-in-class oral therapeutic option for children with achondroplasia, potentially offering families greater control and choice in treatment options.
BridgeBio Pharma (Nasdaq: BBIO) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BBP-812, its gene therapy program for Canavan disease. This designation is based on promising clinical evidence from the CANaspire Phase 1/2 trial, which showed functional improvements in all dosed patients. RMAT status offers benefits like faster and more frequent FDA interactions, potentially accelerating the approval process.
Key points:
- BBP-812 is an intravenous AAV9 gene therapy for Canavan disease
- All patients in the trial showed improvements in key functional areas
- The therapy has been well-tolerated with a safety profile consistent with other AAV9 gene therapies
- BBP-812 also has Orphan Drug, Rare Pediatric Disease, and Fast Track Designations
If approved, BBP-812 could be the first treatment option for this fatal neurodevelopmental disorder.